Transplant and Surgical Oncology: Global Activity, Capacity and Access

Summary

Transplant and surgical oncology sit within healthcare delivery, covering solid organ transplantation and the surgical treatment of cancer. Reported global transplant activity reached 173,727 solid organ transplants in the latest available data, with kidney transplantation the largest group ¹. Even so, transplant activity covers at most 10% of estimated global need ². Cancer surgery shows a similar gap: over 80% of new cancer cases are estimated to need surgery ⁶, yet fewer than 25% of patients worldwide receive surgery that is safe, affordable and timely ⁶. Workforce shortage is the central constraint, with a reported shortage of nearly 199,000 surgeons ¹⁵ and a modelled optimal workforce of 1,416,000 surgeons ⁷. Liver surgery evidence favours high-volume centers ¹⁰. Verified market size, payer mix, and digital health data were not found. Main risks are inconsistent counts across sources and concentration of services in urban areas ¹³. Outlook: activity is growing, but access inequity persists.

Key findings

1. 1

   Transplant activity is growing but remains well below need

   Reported global solid organ transplants rose 2% to 173,727, and the reporting body estimates activity covers at most 10% of global needs. The 10% figure is an estimate and an upper bound.

   Confidence: High
2. 2

   Living and donation after circulatory death sources are expanding

   DCD donation rose 17% and accounted for 28% of deceased donation activity. Living donors contributed 37% of kidney transplants and 23% of liver transplants.

   Confidence: High
3. 3

   Cancer surgery access is the main gap

   Over 80% of new cancer cases are estimated to need surgery, but fewer than 25% of patients receive safe, affordable and timely surgery. The 25% figure is an upper bound from an older commission report.

   Confidence: Medium
4. 4

   Surgeon workforce shortfall is large

   A shortage of nearly 199,000 surgeons is cited, and a modelled optimal workforce of 1,416,000 surgeons is a forecast across 183 countries. Both are modelled or cited estimates.

   Confidence: Medium
5. 5

   Higher-volume centers show better liver surgery outcomes

   A pooled analysis of 20 studies with 248,707 patients found an odds ratio for mortality of 0.52 for high-volume versus low-volume hospitals (95% credible interval 0.41 to 0.65). A Netherlands audit did not find a volume-outcome association, so the evidence is not uniform.

   Confidence: High
6. 6

   Reliable market and payer data are missing

   No verified global market size, reimbursement mix, or public, private and community provider split was found for these services. Conclusions on commercial structure are therefore qualitative.

   Confidence: Qualitative

1Industry definition and scope

This report covers two linked service areas: solid organ transplantation (kidney, liver, heart and lung) and surgery for cancer. Transplantation activity depends on deceased donation after brain death, donation after circulatory death (DCD), and living donation. Surgical oncology covers cancer resections performed by surgical teams, supported by anaesthesia and facilities.

The geographic scope is global. Transplant figures come from the Global Observatory on Donation and Transplantation, which reports on 92 countries in one dataset ¹ and on 96 countries in a later provisional release ³. Surgical oncology evidence comes from global and regional studies, several of which predate the latest transplant data ⁶¹³.

Terminology is not fully consistent. One source reports solid organ transplants ¹, while another reports all organ transplants ³. This report uses solid organ transplants unless a source states otherwise. The report describes evidence and market structure only and is not individual medical, legal or investment advice.

• Reported global solid organ transplants 173,727transplants Observed Global, 92 reporting countries, Latest available data [1]

Scope is set by the sources available in the pack. No external definitions were added.

2Market size, structure and value chain

No verified global market size or revenue figure exists in the pack for transplant or surgical oncology services. The report therefore measures activity rather than value. Activity is rising: the observatory reports a 2% increase to 173,727 solid organ transplants ¹, while a later provisional release reports 183,896 organ transplants from 96 countries, a 4% increase ³. A peer-reviewed analysis reports that global transplants rose 76%, from 101,990 to 179,091, across its study period ⁴. These growth figures use different counts and periods and should not be combined.

Kidney transplantation accounts for the largest share of procedures, followed by liver, heart and lung ¹. The reported kidney count is 110,467 across 90 countries ¹. Donor supply is a key structural element. The observatory estimates about 47,180 actual deceased donors, of whom 13,366 were DCD donors ². Living donors contributed 37% of kidney transplants and 23% of liver transplants ².

The value chain, as the report interprets it, runs from donor identification and consent, through donation and organ allocation, to surgery, peri-operative care and follow-up. For cancer, it runs from diagnosis and multidisciplinary referral, through resection and anaesthesia, to adjuvant care. The pack does not describe payment flows or revenue models. Key stakeholders named in the pack are national transplant organizations and governments ³, professional societies that set training standards ¹⁵, and hospitals that perform volume-sensitive procedures ¹⁰.

Table uses only figures in the pack. Market value is not estimated.

3Customers, demand and adoption

The end users are patients who need transplantation or cancer surgery, and the health systems that pay for and provide these services. The observatory notes long waiting lists but does not verify their duration ¹. Verified waiting-time and waiting-list mortality data are not available in the pack.

Demand for cancer surgery is large. The commission estimates that over 80% of 15.2 million new cancer cases need surgery, some more than once ⁶. The 80% figure is an estimate. A modeling study across 183 countries estimated future demand and workforce needs ⁷. Demand is also shaped by access: an estimated two billion people lack access to any surgical care, including cancer surgery ¹³. Surgical services tend to cluster in urban areas, and cancer surgery access is likely worse than general surgery ¹³.

Purchasing criteria are not documented in the pack. The commission frames performance in terms of safe, affordable and timely surgery ⁶, which suggests these are the criteria most relevant to decision makers. Growth in transplant activity has been concentrated in very-high-HDI countries, and inequity persists across regions ⁴. Barriers therefore include geography, workforce and financing. Changing expectations are not verified in the pack, and this report does not infer patient preference data.

• Cancer cases estimated to need surgery Over 80percent Estimate Global, Latest available data in cited commission report [6]

Interpretation of demand barriers is the report's own reading of cited evidence.

4Competitive landscape and key players

The pack does not name commercial companies that provide transplant or surgical oncology services. The main providers are national transplant systems, regional networks and hospital centers. Comparable company-level market share and business model data were not found, so comparable examples are limited to systems and regions.

Spain reported 6,336 transplants, a rate of 132.3 per million population, second only to the United States ³. This is a national performance indicator, not a commercial ranking. In Italy, the Veneto region's share of hepatobiliary surgery in highly specialized centers rose from 62% to 78% over the study period ¹¹. Nationally, very high-volume units performed 41.1% of 6,126 liver resections, while very-low-volume units performing 20 or fewer resections accounted for 21.4% ¹². In the Netherlands, higher-volume centers performed more major liver resections and more resections for hepatocellular and biliary cancer ⁹.

These patterns show concentration of complex surgery in fewer centers. The public, private and community split is not verified for any country in the pack, so this report cannot compare ownership models. The strongest competitive pressure in the evidence is therefore regulatory and organizational, not commercial: which hospitals are approved to perform complex cases. This is the report's interpretation. Fair comparison is limited because the countries differ in data systems and definitions.

No company names are used because none appear in the pack. Comparisons are limited to systems and regions.

5Technology, operations and workforce

Verified technology adoption metrics for transplant or surgical oncology are not in the pack, and no digital health adoption figures were found. The clearest operational signal is the rise of DCD donation, which grew 17% and reached 28% of deceased donation ¹. This suggests that donor pathway practice is changing, though the pack does not describe the technical changes involved.

Outcome evidence links operational scale to quality. In a pooled analysis of 20 studies covering 248,707 patients, high-volume liver resection hospitals had lower mortality than low-volume hospitals ¹⁰. A nationwide cohort found liver transplant recipients at high-volume hospitals had lower rates of acute renal failure and mortality ¹⁴. These findings support volume-based referral, but the Netherlands audit found no volume-outcome association ⁹, so the evidence is not uniform.

Workforce is the main capacity constraint. A narrative review identifies surgeon shortages, fragmented training and financial constraints as drivers of access gaps ⁸. The cited shortage is nearly 199,000 surgeons ¹⁵. A modeling study estimates an optimal workforce of 1,416,000 surgeons across 183 countries ⁷. A consensus curriculum offers resource-stratified training scaffolding ¹⁵. A commission proposes nine solution domains and eight actions to improve access ⁵. Skill supply and business model change are not quantified in the pack.

• Optimal surgical workforce for cancer surgery 1,416,000surgeons Forecast Global, 183 countries modelled, Modelled target in cited study [7]

The shortage figure is cited secondhand in the consensus statement and is treated as an estimate.

6Regulation, standards, risk and sustainability

The pack does not include verified national laws, regulatory texts or licensing rules for transplantation or cancer surgery in any jurisdiction. The report therefore cannot distinguish binding requirements from proposed rules for specific countries. Where the pack refers to standards, they are voluntary or advisory: the consensus curriculum for surgical oncology ¹⁵ and the commission recommendations ⁵. Neither is binding in the sources provided.

Quality and safety expectations are framed around safe, affordable and timely surgery ⁶. Registry-based evidence shows that outcomes differ by volume, which supports quality monitoring ¹²¹¹. Outcome registries contain patient-level data, so privacy protection and data governance are important, though the pack does not describe the rules that apply. Ethical questions arise in donation and allocation, and a peer-reviewed analysis calls for policy responses to global inequities ⁴. The pack does not verify specific policy instruments.

Operational risks include uneven access and workforce shortage ⁸¹³. Data inconsistency is a material risk for planners: the same system reports different totals and country counts ¹³. Sustainability and environmental impacts are not covered in the pack. Readers in regulated settings should consult the relevant national authorities and clinical governance bodies. This section is not legal or clinical advice.

No binding regulatory provisions were verified for any country, so none are asserted.

7Challenges, opportunities and case examples

The main challenges are access, workforce and financing. Surgical oncology suffers from marginal gains despite growing visibility, and few plans fund basic cancer surgical services ⁵. Financial constraints and fragmented training add to these pressures ⁸. Transplant activity remains constrained relative to need ², and concentration of gains in high-HDI countries limits global equity ⁴.

Opportunities follow the evidence. Expanding DCD donation has grown quickly ¹. Living donation supplies a large share of kidney and liver transplants ². Volume-based referral of complex liver cases is supported by outcome evidence ¹⁰¹⁴. Training frameworks that can be adapted by resource level offer a route to build capacity ¹⁵. These opportunities are the report's interpretation and are not market forecasts.

Case examples: Spain reports a high national transplant rate, 132.3 per million ³. The Veneto region of Italy concentrated hepatobiliary surgery in specialized centers, reaching 78% of procedures, with lower mortality at high-volume centers ¹¹. Italy's national registry shows a large share of liver resections in very high-volume units ¹². The Netherlands audit links higher volume to more complex resections ⁹. These are system-level examples. Comparable company examples are not in the pack, and the report does not infer commercial performance.

Examples are limited to four national or regional systems because no company examples are in the pack.

8Outlook and strategic implications

In the near term, transplant activity is likely to keep growing, based on recent increases in global totals ¹³ and the rise in DCD donation ¹. Growth is uneven, and gains have been concentrated in very-high-HDI countries ⁴. Cancer surgery demand will rise with the number of cases needing surgery ⁶, while workforce capacity grows slowly against modelled needs ⁷¹⁵. These trends are the report's interpretation of cited evidence.

In the medium term, the main uncertainty is whether workforce and financing can close the gap. The cited commission notes few plans to fund basic cancer surgical services ⁵, which suggests that access gains may lag activity growth. Data quality is another uncertainty, given inconsistent counts across sources ¹³. Stakeholders should monitor these indicators before drawing firm conclusions.

Practical implications are limited to evidence-based steps. Health planners could consider volume-based referral for complex liver surgery ¹⁰¹⁴. Training bodies could adopt resource-stratified curricula ¹⁵. Funders should track access measures such as the share of patients receiving timely surgery ⁶. Industry participants should note the absence of verified market and payer data before investing in these areas.

No quantitative scenario model is supported by the pack.

9Conclusion

Transplant and surgical oncology are growing in activity but remain far from meeting need. The most defensible takeaways are that transplant activity covers at most 10% of need ², that fewer than 25% of cancer patients receive safe, affordable and timely surgery ⁶, and that surgeon capacity is the binding constraint ¹⁵⁷. Market value and payer data remain unverified.

How this was built

Sources

1. 1

   Organ Donation and Transplantation Worldwide: The Global Observatory on Donation and Transplantation Report

   Global Observatory on Donation and Transplantation (WHO collaborating center, managed by Organización Nacional de Trasplantes) Official statistics

   pmc.ncbi.nlm.nih.gov
2. 2

   Global Observatory on Donation and Transplantation international report (data tables)

   Global Observatory on Donation and Transplantation Official statistics

   transplant-observatory.org
3. 3

   Global Observatory on Donation and Transplantation provisional data (Spain government news release)

   La Moncloa (Government of Spain), citing Global Observatory on Donation and Transplantation Official statistics

   lamoncloa.gob.es
4. 4

   Global inequities in organ transplantation: trends, unmet need, and policy implications

   Peer-reviewed study using GODT data (authors not confirmed in retrieved text) Peer-reviewed

   ncbi.nlm.nih.gov
5. 5

   Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide

   Are C, Murthy SS, Sullivan R et al., The Lancet Oncology Commission Peer-reviewed

   sciencedirect.com
6. 6

   Global cancer surgery: delivering safe, affordable, and timely cancer surgery

   Sullivan R et al., Lancet Oncology Commission Peer-reviewed

   thelancet.com
7. 7

   Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce

   Perera SK, Jacob S, Wilson BE et al., The Lancet Oncology Peer-reviewed

   thelancet.com
8. 8

   Global Cancer Surgical Workforce Challenges and Proposed Initiatives

   Peer-reviewed narrative review (authors not confirmed in retrieved text) Peer-reviewed

   link.springer.com
9. 9

   Volume-outcome relationship of liver surgery: a nationwide analysis (Dutch Hepato Biliary Audit)

   Peer-reviewed study, Netherlands nationwide cohort (authors not confirmed in retrieved text) Peer-reviewed

   ncbi.nlm.nih.gov
10. 10

    The impact of hospital volume on liver resection: A systematic review and Bayesian network meta-analysis

    Peer-reviewed systematic review, Surgery journal (authors not confirmed in retrieved text) Peer-reviewed

    surgjournal.com
11. 11

    Trends in hospital volume and operative mortality in hepato-biliary surgery in Veneto region, Italy

    Peer-reviewed study, Veneto region administrative cohort (authors not confirmed in retrieved text) Peer-reviewed

    pubmed.ncbi.nlm.nih.gov
12. 12

    6,126 hepatectomies: current trend of outcome in Italy

    Peer-reviewed nationwide study using Piano Nazionale Esiti registry data Peer-reviewed

    link.springer.com
13. 13

    Global Surgery: Surgical Services for Cancer Care

    Disease Control Priorities, third edition (book chapter) Peer-reviewed

    ncbi.nlm.nih.gov
14. 14

    Global Cancer Surgery: Liver transplantation volume and acute renal failure (PLOS ONE nationwide cohort)

    Peer-reviewed nationwide cohort study (authors not confirmed in retrieved text) Peer-reviewed

    journals.plos.org
15. 15

    Global curriculum in surgical oncology: 2nd edition

    Society of Surgical Oncology and European Society of Surgical Oncology (consensus statement) Peer-reviewed

    sciencedirect.com